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We previously reported that activation of the host autophagic protein, Beclin1, by HIV-1 infection 
represents an essential mechanism in controlling HIV replication and viral-induced inflammatory 
responses in microglial cells. Existing antiretroviral therapeutic approaches have been limited in their 
ability to cross the blood-brain barrier effectively and recognize and selectively eliminate persistent 
HIV-infected brain reservoirs. In the present study and for the first time, the bio-distribution and 
efficacy of noninvasive intranasal delivery of small interfering RNA (siRNA) against the Beclin1 gene 
using the cationic linear polyethylenimines (PEI) as a gene carrier was investigated in adult mouse 
brain. Fluorescein isothiocyanate (FITC)-labeled control siRNA delivered intranasally was found in 
the cytoplasm of neurons and glial cells of the prefrontal cortex at 4 and 24 hours post-delivery, with 
no major adverse immune reaction encountered. Intranasal delivery of the siRNA targeting Beclin1 
significantly depleted the target protein expression levels in brain tissues with no evidence of toxicity. 
Binding of siRNA to PEI-polymer was characterized and confirmed by Raman spectroscopy. These 
results indicate that the intranasal drug delivery allows for the direct delivery of the PEI-siRNA nano-
complex to the central nervous system, which could potentially offer an efficient means of gene 
silencing-mediated therapy in the HIV-infected brain.
In spite of a dramatic reduction in human immunodeficiency virus (HIV)-associated dementia (HAD), HIV 
RNA copy number and great improvement in the survival rate among people living with HIV using long-term 
combined anti-retroviral therapy (cART), virus persistence continues in latent virus reservoirs and the virus can 
re-populate once cART is discontinued [Reviewed in ref.1. The blood-brain barrier (BBB) tightly controls the 
trafficking of substances between the blood and brain and many of the widely used antiretroviral drugs available 
poorly penetrate the central nervous system (CNS). In addition, cART is not totally effective in controlling HIV 
replication in brain cells and does not directly target the inflammatory cascades which are believed to be the pri-
mary cause of neuronal injury or dysfunction related to HAD pathology2–5.
Despite their instability and potential to induce insertion mutagenesis, toxicity, and immunogenicity, in recent 
years the use of RNA interference (RNAi)-based therapeutics such as small interfering (si)/short hairpin (sh)
RNAs to mediate silencing of gene expression has shown exciting prospects for the development of novel thera-
peutic strategies6. With brain being the target organ for HAD, it represents an additional impediment in delivery 
of si/shRNA due to the presence of the BBB7,8. Encapsulating siRNA within nanoparticles not only protects the 
RNA from nucleases but also shields its overall negative charge, which can prolong the in vivo circulation life in 
blood and facilitate its passage across the cell membrane to the cytoplasm of target cells9. As shown by others, 
numerous non-viral strategies for si/shRNA delivery based on lipids10,11, biocompatible polymers/dendrimers12,13, 
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polypeptides14 and inorganic materials15,16 have been implemented and are currently under investigation. One 
in particular is the biodegradable linear polymer cationic polyethylenimines (PEI) which have been used effi-
ciently for the delivery of plasmid DNA17 and siRNAs18,19. The success by which the nanoparticle-based RNAi 
is delivered to brain is dependent on several factors, including the route of administration20. The non-invasive 
intranasal method of drug delivery is not obstructed by the BBB and allows molecules that do not cross the BBB 
direct access to the CNS21. Delivery from the nose to the CNS occurs within minutes along both the olfactory and 
trigeminal neural pathways via an extracellular route and does not require drug to bind to any receptor or axonal 
transport21. Efficacy of therapeutics administered intranasally in mice has been demonstrated in a number of 
studies including for insulin in diabetic mouse models22–24 and deferoxamine in Alzheimer’s mouse models25,26.
In the present study, we investigated the therapeutic potential of intranasal siRNA delivery in adult mice using 
siRNA targeting the Beclin1 (Atg6) gene in complex with PEI. Beclin1 is an essential protein in regulating auto-
phagic activity by acting as a platform to recruit and activate positive regulators such as phosphatidylinositol-3 
kinase (PI3KCIII/Vps34) complexes that mark membranes for autophagosome generation and facilitate auto-
phagosome fusion with lysosomes, and also recruit negative regulators, thereby blocking vesicle nucleation and 
autophagy maturation [reviewed in ref.27. We have discovered that activation of the host autophagic pathway by 
HIV-1 infection represents an essential mechanism in controlling viral replication and viral-induced inflamma-
tory responses in microglial cells28. The purpose of this study was to examine the bio-distribution and efficiency 
of intranasal delivery of siRNA to the brain and to investigate target gene silencing efficiency and possible toxicity 
in different brain regions. Altogether, our data shows optimization of the efficacy of siBeclin1 in attenuating HIV 
replication and HIV-induced inflammatory responses in vitro for in vivo use, the feasibility of using PEI reagent 
as gene carrier, and the bio-distribution of the nano-complex in brain via intranasal delivery.
Results
Formation of PEI-FITCsiRNA nanoplexes used for intranasal administration. Fluorescein isothio-
cyanate (FITC)-labeled control siRNA (2 µg) or Beclin1 siRNA (16 µg) forms a complex through binding with the 
linear polyethylenimine (PEI)-based cationic polymer, in vivo jetPEI, which can be used as gene carrier for intra-
nasal delivery (Fig. 1A). In vivo jetPEI is a biodegradable polymer, which shows maximum siRNA delivery effi-
ciency at an N/P ratio of 7.029–31. H&E staining of prefrontal cortex from mouse brain tissues after 4 and 24 hours 
administration (Fig. 1B) showed normal cell morphology with minimal vacuolation in PEI-FITCsiRNA and 
PBS treated tissues. Moreover, the granule cell layer appeared undisrupted and there were no signs of aberrant 
morphology of purkinje neurons and astrocytes. This suggests that intranasal administration of PEI-FITCsiRNA 
nanoplexes does not exert any noticeable tissue toxicity.
Cell-type distribution of PEI-FITCsiRNA nanoplexes after intranasal delivery in mouse 
brain. We next examined the efficiency of intranasal siRNA delivery in normal mouse brain by triple fluo-
rescence imaging using the FITC-labeled control siRNA, cell-type-specific immunolabeling, and DAPI staining 
(Fig. 2). Four hours post-delivery mouse brain (frontal cortex) treated with PBS was examined with DAPI (blue), 
the microglial marker, Iba1 (red), the astrocyte marker, GFAP (red), and the neuronal marker, Map2 (red), respec-
tively (Fig. 2A). In similar fashion, mouse brains treated with PEI-FITCsiRNA at 4 hours post-delivery (Fig. 2B) 
were examined with antibody against microglia (left panel), astrocytes (middle panel) and neurons (right panel), 
DAPI, and green fluorescence. Figure 2C represents mouse brain (frontal cortex) treated with PEI-FITCsiRNA 
after 24 hours. The data shows the successful delivery of siRNA in different cell types of the prefrontal cortex 
as soon as 4 hours after intranasal administration, and the presence of siRNA was still detected after 24 hours 
of administration. The other half of the brain hemisphere was minced and used to detect for inflammatory 
Figure 1. PEI-siRNA formulation and mouse brain histology after intranasal administration of nanoplexes. 
(A) Schematic representation of the PEI-siRNA formulation and intranasal administration to adult C57BL/6 J 
mice (n = 3/treatment). (B) Representative images of Hematoxylin-eosin stained sections of brain tissues 
after 4 hours (at 20X magnification) and 24 hours of intranasal administration of PBS (upper panel) and PEI-
FITCsiRNA (lower panel) at 20X and 63X magnification.
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responses looking at the release of IL-6, MCP-1 and RANTES by ELISA which showed no significant increase 
with PEI-FITCsiRNA when compared to PBS treated mice at 4 and 24 hours (Fig. 2D). Overall, this data suggests 
that PEI-FITCsiRNA nanoplexes can be successfully delivered to the brain and colocalized in brain cells without 
any significant inflammatory molecule release.
Presence of PEI-FITCsiRNA nanoplexes in lungs after intranasal delivery. Since the lungs are 
directly connected with the nasal cavity through the pharynx and upper and lower respiratory passages32, we 
determined whether off-target organs, such as the lungs, were affected by intranasal administration at 24 hours 
post-delivery. The distribution of the nanoplex as measured by green fluorescent signals were found in ciliated 
epithelial cells (arrows) when compared to PBS treated lungs (Fig. 3A,B, left panel). In addition, based on bright-
field microscopy, no morphological differences were detected in the lung tissues with the different treatments 
(Fig. 3A,B, right panel). Since we were able to detect green fluorescence, we measured inflammation by ELISA 
using the other half of the lung. Release of IL-6, MCP-1 and RANTES was measured and showed no significant 
increase in pro-inflammatory responses with PEI-FITCsiRNA when compared to PBS treated mice (Fig. 3C). 
Overall, the data confirms the effective delivery of PEI-FITCsiRNA nano-formulation to the brain with minimal 
off-target effects to the lungs.
Titration of siBeclin1 in HIV-infected primary human microglia. In our recently published data we 
confirmed that 2 µg of siBeclin1 was efficient in attenuating HIV replication and HIV-induced inflammation 
using in vitro cell culture conditions16,28. However, since we detected presence of FITCsiRNA in the lungs after 
intranasal administration (Fig. 3), we performed a titration curve using increased amount of siBeclin1 (4, 8 and 
16 µg) in order to ensure that sufficient Beclin1 siRNA would be delivered to the brain in animal studies. As 
expected, viral titer as detected by HIV-1 p24gag protein ELISA showed a significant reduction in the supernatant 
of microglia after 24 hours transfection with 4 µg siRNA, although viral reduction was more efficient at 16 µg 
(Fig. 4A). In fact, viral titer was reduced by ~50% at 4 µg, and by ~75% at 16 µg treatment when compared to 
HIV-1-infected cells alone. To determine whether the functional effects of siBeclin1 at the different amounts 
can lead to cell death, viability was assessed after 24 hours treatment using a live/dead cell assay. No significant 
differences were observed in the viability of infected microglial cells under the different treatment conditions 
(Fig. 4B). The silencing efficiency of siBeclin1 (at 16 µg) in HIV-1-infected microglia, as determined by Western 
blotting analysis, showed a robust inhibition of Beclin1 protein expression after 24 hours transfection (Fig. 4C). 
Inflammatory responses in the supernatant of microglial cells measured by ELISA showed significant reductions 
Figure 2. Cell-type distribution of PEI-FITCsiRNA in mouse brain following intranasal administration. 
Representative images of brain sections immunolabeled with antibodies to the microglial marker, Iba1 (left 
panel), astrocyte marker, GFAP (middle panel), and neuronal marker, Map2 (right panel), in red for (A) PBS 
treatment, and PEI-FITCsiRNA (indicated by green fluorescence) administration for (B) 4 hours and (C) 
24 hours. DAPI (blue) staining indicates cell nuclei at 63X magnification. (D) The other half of brain tissues was 
used to detect the indicated cytokines and chemokines by ELISA after 4 and 24 hours. Values were determined 
from standard curves and are presented as the mean ± the standard error of the mean (S.E.M.) of three 
independent experiments.
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in the levels of IL-6, RANTES and MCP-1, and the reduction was dependent on the siBeclin1 concentration used 
(Fig. 4D). Twenty-four hours post-treatment with 4, 8 and 16 µg of siBeclin1 caused a significant decrease of 25%, 
35%, and 55% in the release of IL-6, respectively, a significant decrease of 26%, 30% and 54%, respectively, in the 
release of RANTES and a significant decrease of 27%, 32% and 50%, respectively, in the release of MCP-1 when 
compared to HIV-infected microglial cells alone. Efficacy of siBeclin1 was also measured in HIV-infected human 
astrocytes and showed similar pattern in viral attenuation and in the reduction of inflammatory molecules as with 
microglia cells (data not shown). In summary, the in vitro data suggests that siBeclin1 (at 16 µg) was most effective 
in attenuating HIV titer and viral-induced inflammation in glial cells and therefore chosen in subsequent in vivo 
intranasal experiments.
Raman spectroscopic evaluation of the PEI-siBeclin1 formulation for intranasal administra-
tion. Prior to intranasal administration, we assessed the binding efficiency of PEI-siBeclin1. The assessment of 
functional groups exhibited by the PEI-siBeclin1 formulation was characterized stepwise using Raman spectros-
copy as shown in Fig. 5A. The Raman spectroscopic features were characterized in the region ranging from 2200 
to 400 cm−1 because PEI and base pairs along with major functional groups of nucleic acids are more responsive 
in the selected region33. The Raman spectrum of PEI (curve a) exhibited an intense sharp band at 1600 cm−1 that 
is due to the amine group (N-H bending) and a broad intense band at 1380 cm−1 attributed to the vibration of 
C-N and C-H bending in the methyl group33,34. A low intensity weak band observed at 735 cm−1 is attributed to 
rocking and vibration of ethylene of PEI33. The Raman spectrum of siBeclin1 exhibited all optically active modes 
which corresponds to bases present in nucleic acid (curve b). The observed Raman bands at 510 cm−1 (G, U), 
580 cm−1 (C;G), 630 cm−1 (A), 682 cm−1 (G), 760 cm−1 (U;d), 1050 cm−1 (d-CO), 1121 cm−1 (d-PO2−), 1253 cm−1 
(C), 1365 cm−1 (U;A;G), and 1450 cm−1 (d (CH2)) are present in the nucleic acid chain33,35. The spectral region 
ranging from 800 to 1000 cm−1, which corresponds to the RNA backbone, exhibited Raman bands at 840 and 
910 cm−1 that are attributed to O-P-O stretching vibration related with DNA structure and the phosphate-ribose 
backbone, respectively33–35.
Next, we observed that the PEI-siBeclin1 formulation exhibited all the Raman responsive modes as shown by 
PEI and siBeclin1 alone, suggesting the presence of Beclin1 siRNA and PEI. However, the intensity of the very 
sharp intense band at 1600 cm−1 exhibited by PEI was reduced remarkably and shifted to a higher wavelength, 
~1700 cm−1. This might be due to possible binding between the amine group of PEI and base pairs of siBeclin1. 
Also, the other Raman bands exhibited by the PEI-siBeclin1 formulation were broader than those observed for 
siBeclin1. This may be due to possible ionic interaction between PEI and siBeclin1. The results of the Raman 
study showed that PEI and Beclin1 siRNA exhibited bands related with the functional groups of the individual 
Figure 3. Distribution of PEI-FITCsiRNA nanoplexes in mouse lung following intranasal administration. 
Representative images of lung sections stained with DAPI (blue) to label cell nuclei after 24 hours of intranasal 
administration of PBS (A, left panel) and PEI-FITCsiRNA (B, left panel). Arrows indicate the presence of green 
fluorescent signals in the ciliated epithelial cells at 63X magnification. (A,B, right panel) Respective bright 
field images for morphology confirmation. (C) The other half of lung tissues was used to detect the indicated 
cytokines and chemokines by ELISA. Values were determined from standard curves and are presented as the 
mean ± the standard error of the mean (S.E.M.) of three independent experiments.
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materials. However, the Raman bands exhibited by the formulation correlated with functional groups of PEI and 
siBeclin1, confirming complex formation without losing functionality, as discussed and validated through in vitro 
assays.
Intranasal delivery and efficacy of PEI-siBeclin1 nanoplexes in mice. Next, we assessed the 
bio-distribution and efficacy of siBeclin1 (16 µg) delivered intranasally in the brain of normal adult mice (Fig. 5). 
We examined whether intranasally delivered siBeclin1 caused target gene silencing in brain regions of the pre-
frontal cortex (Fig. 5B) and striatum (data not shown). The striatum and prefrontal cortex are areas of inter-
est, since high levels of HIV are found in the striatal region of post-mortem patients and HIV causes striatal 
dysfunction leading to motor deficits36–38. Twenty-four, 48, 72 and 120 hours post-delivery of the nanoplex, 
Beclin1 silencing in the frontal cortex by intranasally delivered siBeclin1 was confirmed by immunoblot analy-
sis. Protein expression was significantly downregulated by 65% after 24 hours and 43% after 48 hours (Fig. 5B), 
while downregulation by siBeclin1 was minimally detected after 72 hours and Beclin1 expression was recovered 
after 120 hours (Fig. 5B). Release of IL-6, MCP-1 and RANTES by ELISA showed no significant increase with 
PEI-siBeclin1 when compared to PBS treated mice (data not shown). H&E staining from the prefrontal cortex of 
PEI-siBeclin1 treated brain tissues at 24, 48, 72 and 120 hours post-delivery did not show myelin vacuolation, a 
characteristic indication of neurotoxicity, when compared with the PBS control group (Fig. 5C). There was also 
no noticeable neuronal swelling detected, and the normal presence of astrocytes in pairs was observed in tissues 
exposed to PEI-siBeclin1 and PBS (arrows). Similarly to the brain, PEI-siBeclin1 did not cause detectable tissue 
damage in the lung, liver, kidney, spleen or heart after intranasal delivery (see Supplementary Fig. S1). Overall, the 
data shows efficient delivery of siBeclin1 and downregulation of Beclin1 protein expression using in vivo jetPEI, 
and most importantly that intranasal delivery of siBeclin1 did not cause noticeable detrimental effects to the brain 
and lung tissues as well as other main organs.
Discussion
In recent years, the efforts made to develop RNAi-based therapies to mediate silencing of gene expression have led 
to productive research in the field of numerous infectious diseases affecting humans, including HIV39–45. Despite 
the high potential use of antisense therapy, its clinical application is limited mainly due to its short half-life in 
Figure 4. Titration of siBeclin1 achieved attenuation of HIV-1 replication and -induced inflammation in vitro. 
(A) HIV-1 replication in human microglia transfected with the indicated amounts of siBeclin1 was measured 
using HIV-1 p24gag protein ELISA. Values were determined from standard curves and are presented as the 
mean ± the standard error of the mean (S.E.M.) of three independent experiments (*p < 0.05 vs. HIV; # vs. 
siBeclin1 4 µg). (B) Cell viability assay performed following the indicated treatments showed no significant 
microglial cellular toxicity. Data are presented as percentages of viable cells ± the S.E.M. from three independent 
experiments. (C) Cell lysates from microglia with the indicated treatments were subjected to immunoblotting 
with antibodies to Beclin1 and GAPDH as a loading control. (D) Corresponding cell culture supernatants 
used for p24 ELISA were used to detect the cytokines and chemokines IL-6, RANTES and MCP-1 by ELISA. 
Values were determined from standard curves and are presented as the mean ± the S.E.M. of three independent 
experiments (*p < 0.05 vs. HIV; # vs. siBeclin1 4 µg).
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vivo, lack of target cell specificity, and poor transport across the cell membrane46. However, packaging siRNA 
within nanoparticles has proven to protect nucleotides from the complex biological environment by shielding 
the overall negative charge of siRNA, increasing its stability and preventing RNase cleavage. Various strategies 
have been examined to improve delivery efficiencies of drugs to the brain. The application of drugs encapsu-
lated into non-viral vectors, like synthetic nanoparticles, was found to enhance delivery to neuronal cells and the 
brain itself 21,26,47. Using electro-magnetic nano-material (CoFe2O4@ BaTiO3; MENP) bound to siRNA targeting 
Beclin1, we showed that MENP-siBeclin1 can cross an artificial BBB and attenuate the neurotoxic effects of HIV-
1-infected microglia following on-demand release of siRNA using an in vitro primary human BBB model16.
The present study demonstrates the successful intranasal delivery of PEI-siRNA nanoplexes and subsequent 
silencing of Beclin1 protein expression in different brain regions including the cerebral cortex and striatum. 
Targeting Beclin1 is of relevance since numerous evidence has shown that autophagy is a critical target for HIV 
during the viral life cycle which has led to an increasing effort to understand the role of autophagy in those cells 
affected by HIV infection48–50. The autophagy pathway engulfs and degrades cytoplasmic cargo through lysoso-
mal degradation [reviewed in ref.27, and plays a crucial role in defense against microbial infections, neurodegen-
erative disorders, cancer and aging51. Specific autophagy-inducing agents are being considered for therapeutic 
treatment and prevention of a broad range of human diseases52–55. In Fig. 1, we developed a nanoplex composed 
of linear cationic polyethylenimines (PEI) bound to siRNA that was delivered through intranasal administration 
in adult mice. PEI has a high transfection efficiency both in vivo and in vitro, and was initially used as an effi-
cient non-viral transfection reagent for the delivery of plasmid DNA17. In recent years, PEI-mediated delivery of 
nucleic acids was extended towards siRNAs as well18,19. Due to its high cationic charge density and a large number 
of protonable nitrogen atoms, PEI is able to form stable, water-soluble, non-covalent complexes with nucleic 
acids. According to the literature, these PEI complexes are efficiently taken up by cells through endocytosis and, 
based on their unique property of acting as a “proton sponge”, the continuous proton influx induces endosome 
osmotic swelling and rupture which provides an escape mechanism for siRNA particles intracellularly without the 
support of endosomal disruptive agents for lysosomal escape56. The proton sponge effect buffers the endosomal 
pH and protects the siRNA from degradation56. It is important to note that the transfection reagent used here, 
in vivo-jetPEI (Polyplus), is being used in preclinical studies and phase I and II clinical trials, although mainly 
for cancer therapies57,58. As shown in Fig. 2, PEI-siRNA nanoplexes can be efficiently delivered to different cell 
types in the brain via the intranasal route, without noticeable evidence of toxicity (Fig. 1B), although low levels of 
Figure 5. PEI-siBeclin1 binding analysis and functionality assessment following intranasal administration. 
(A) Raman spectroscopic study of PEI (curve a), Beclin1 siRNA (curve b), and the formulation consisting 
of PEI and siBeclin1 bound as a complex (curve c). Abbreviations used are defined as indicated. (B) Beclin1 
silencing efficiency was measured by western blotting analysis using lysates from brain tissue after intranasal 
administration of the indicated treatments. Representative western blot images and graphical representations 
showing Beclin1 expression normalized to β-actin (loading control) at the indicated time points are presented. 
Error bars show the standard error of the mean (S.E.M.) of three independent experiments (*p < 0.05 vs. 
PBS). (C) Representative images of Hematoxylin-eosin stained sections of brain tissues at the indicated time 
points after intranasal administration of PBS (upper panel) and PEI-siBeclin1 (lower panel) at the indicated 
magnifications. Arrows and labels indicate distinctive cellular morphology.
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green fluorescence were detected in the lungs from animals treated with PEI-FITCsiRNA after 24 hours (Fig. 3B). 
We have previously shown that silencing Beclin1 with siBeclin1 (2 µg) represents an essential mechanism in 
controlling HIV replication and viral-induced inflammatory responses in microglial cells in vitro28. Low level 
detection of siRNAFITC in the lungs (Fig. 3) prompted us to perform a titration curve to determine a higher, yet 
effective concentration of siBeclin1 in attenuating HIV replication and viral-induced inflammation in human 
glial cells for in vivo intranasal delivery use (Fig. 4). Binding and PEI-siBeclin1 nanoplex formation as determined 
by Raman analysis (Fig. 5) and a robust downregulation of the Beclin1 protein as determined by western blotting 
(Fig. 5), without exerting noticeable toxicity to the brain tissue, provides a proof-of-concept on the functionality 
of our designed nanoplex and intranasal delivery. Our study used intranasal delivery, which is a noninvasive 
method to rapidly deliver drugs directly from the nasal mucosa to the brain and spinal cord bypassing the BBB, 
with the aim of treating CNS disorders while minimizing systemic exposure21. Although numerous studies have 
demonstrated the efficacy of drug delivery via the intranasal route to treat animal models of CNS diseases59–62, 
importantly, this mode of transmission has also shown great success in drug delivery in several human stud-
ies63–66, including clinical phase trials67–69. In one clinical trial, human subjects receiving intranasal administration 
of insulin showed significant alterations in brain functions as well as improved memory and mood70,71, without 
affecting blood glucose and serum insulin levels. In another study, intranasal delivery of insulin in men lead to a 
decrease in food intake, enhancement of postprandial thermogenesis, and a decrease in postprandial serum insu-
lin72,73. Furthermore, intranasal delivery of insulin in patients with amnesic mild cognitive impairment resulted 
in modulated plasma levels of amyloid beta and improved memory, attention, and functional status, suggesting a 
possible role for intranasal delivery of insulin in the treatment of Alzheimer’s disease66. Intranasal administration 
of oxytocin, a neuropeptide with a wide range of effects on human behavior, has been shown to increase social 
interactions, reduce anxiety and psychological stress, and improve emotional recognition in youths with autism 
spectrum disorders74,75. Exogenous administration of the antioxidant, Glutathione, to patients with Parkinson’s 
disease (PD) via intranasal delivery was proven safe and effective with anecdotal case reports of improvement68. 
Since changes in Glutathione have been reported in numerous other disorders of the CNS, including schizophre-
nia, dementia, Huntington’s disease, and autism, the intranasal therapeutic potential of Glutathione may not be 
limited to patients with PD68. Our in vivo mouse model of intranasal administration of siRNA is greatly relevant 
to ongoing studies exploring the use of intranasal delivery of drugs for targeting CNS disorders and it is particu-
larly novel as a therapeutic strategy for HIV neurological complications.
Despite the novelty of this approach, the major challenge with intranasal delivery is to achieve an optimum 
amount of the nanoplexes delivered to the CNS and protection of the lungs from exposure. Therefore, formula-
tional modifications and possible systemic side effects of intranasal delivery require future study. Ongoing studies 
in our laboratory are assessing whether liver and kidney functions are affected after intranasal administration 
of siBeclin1, in conjunction with histopathology and blood toxicity profiles. In conclusion, the present study 
shows the usefulness of linear PEI as a gene carrier in vivo and the effectiveness of intranasal delivery of Beclin1 
siRNA as a promising therapeutic tool for attenuating HIV-1 and viral-induced inflammation in the brain. Future 
applications in our laboratory will be analyzing the effectiveness of PEI-siBeclin1 in attenuating HIV using 
viral-infected humanized severe combined immunodeficiency (SCID) mice.
Materials and Mehods
Cell culture. Commercially obtained primary human microglia (ScienCell Research Laboratories, Carlsbad, 
CA, USA; catalog # 1900) were cultured as per the manufacturer’s protocol.
In vitro HIV-1 infection. Human microglia were infected with HIV-1SF162 (p24 = 1 ng/mL; from Dr. Jay 
Levy76 obtained through the NIH AIDS Research and Reference Reagent Program (Germantown, MD, USA) 
as performed previously28,77,78. HIV-1 infection was confirmed by quantification of p24 levels in culture super-
natants using the RETRO-TEK HIV-1 p24 antigen ELISA kit (ZeptoMetrix, Buffalo, NY, USA) as performed 
previously28,77,78.
Transfection of Beclin1 siRNA into microglial cells. HIV-infected human microglia were transfected 
with Beclin1 siRNA purchased from Santa Cruz Biotechnology (Santa Cruz Biotechnology, Santa Cruz, CA, USA; 
catalog # sc-29797) using INTERFERin-PEI reagent (Polyplus-transfection, New York, NY, USA) for 24 and 
48 hours as per the manufacturer’s protocol.
Intranasal administration of siRNA-PEI nano-complexes into C57BL/6 J mice. C57BL/6 J 
mice (stock # 000664) were procured from The Jackson Laboratory (Bar Harbor, ME, USA) and bred in the 
animal facility at Florida International University. All animal experiments were carried out in accordance with 
the approved IACUC protocol issued by Florida International University. In addition, the intranasal adminis-
tration of siRNA was approved by the IACUC at Florida International University. Fluorescein isothiocyanate 
(FITC)-labeled control siRNA (Santa Cruz Biotechnology; catalog # sc36869), Beclin1 siRNA (Santa Cruz 
Biotechnology) or phosphate-buffered saline (PBS) was administered intranasally in normal adult mice using in 
vivo jetPEI reagent (Polyplus-transfection) according to the manufacturer’s protocol. Briefly, jetPEI and siRNA 
were diluted separately in a 10% glucose solution. The solutions containing siRNA and PEI nanoplexes were 
mixed and incubated for 15 min at room temperature. For titration calculation, the formulation corresponds to a 
nitrogen and phosphate (N/P) ratio of 7. Intranasal administration was performed on lightly anesthetized mice. 
Each mouse was placed on a sterile surgical pad and lightly stretched out to better hold the scruff. With a firm 
grip on the scruff, the mouse was turned on its back while still allowing the mouse to breathe and be comfortable. 
With the neck and chin flat and parallel to the pad, the tip of the pipettor containing the sample was placed near 
the left nostril of the mouse at a 45 degree angle, and about 5 µL of sample was administered to the nostril with 
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a 2–3 sec interval in between for a total of 10 µL/nostril. The mouse was held in this position for 5 sec or until it 
regained consciousness, then the administration step was repeated for the other nostril for a total of 20 µL/mouse. 
After the mouse had received all drops, the animal was kept restrained on its back until the material disappeared 
into the nares and then returned back to its cage. After 4, 24, 48, 72 and 120 hours mice were sacrificed and half of 
the brain hemisphere, liver, lungs, heart, spleen and kidneys were cryopreserved by serial exposure to 10 and 20% 
sucrose, embedded in Tissue Tek optimal cutting temperature compound (Sakura Finetek, Torrance, CA, USA) 
and used for histology and the other half was used for biochemical analysis as described below.
Raman spectroscopic analysis. Raman spectrum of PEI, Beclin1 siRNA, and the PEI-Beclin1 siRNA for-
mulation was recorded using a Nomadic Raman microscope from BaySpec (532 nm laser) (San Jose, CA, USA).
Hematoxylin and eosin (H&E) staining. Brain, liver, kidney, lung, spleen and heart sections of 5 micron 
thickness were stained with H&E. Briefly, tissues were exposed to xylene and re-hydrated with absolute ethanol, 
95 and 70% ethanol, followed by staining with hematoxylin dye for 15 min, prior to washing with distilled water. 
Subsequently, tissue sections were stained with eosin for 20 sec, dehydrated with gradient ethanol after washing 
with tap water, and tissues were then cleared by xylene and mounted using mounting media for visualization. 
Images were acquired using a Zeiss (Germany) inverted fluorescence microscope with a 560 Axiovision camera 
using 20, 40 or 63X objectives.
Immunochemistry. Brain sections of 5 micron thickness were fixed in 4% paraformaldehyde, permeabilized 
with 0.1% Triton X-100, blocked in 10% milk/0.1% goat serum, and immunolabeled with anti-GFAP antibody 
(Millipore, Bedford, MA, USA; catalog # ab5804) at a 1:1000 dilution, anti-Iba1 (Santa Cruz Biotechnology, Santa 
Cruz, CA, USA; catalog # sc32725) at a 1:50 dilution and anti-MAP2 (Millipore, Bedford, MA, USA; catalog # 
MAB378) at a 1:100 dilution. Immunoreactivity was visualized with secondary antibodies from Molecular Probes 
(Carlsbad, CA, USA). DAPI staining was used to label cell nuclei. Images were acquired using a Zeiss (Germany) 
inverted fluorescence microscope with a 560 Axiovision camera.
Western blotting. Whole cell lysates or brain tissues were prepared in RIPA buffer supplemented with a 
mixture of protease and phosphatase inhibitors and separated by SDS-PAGE for immunoblotting. Primary anti-
bodies used were anti-Beclin1 (1:500) from Novus Biologicals (Littleton, CO, USA), anti-β-actin (1:200) from 
Santa Cruz Biotechnology and anti-GAPDH (1:1000) from Sigma-Aldrich (St. Louis, MO, USA). Primary anti-
bodies were followed by incubation with a secondary antibody conjugated to horseradish peroxidase (Millipore, 
Billerica, MA, USA) used at a 1:1000 dilution. The immunoblots were exposed to SuperSignal West Femto 
Substrate (Thermo Scientific, Waltham, MA, USA) and visualized using a ChemiDoc imaging system (Bio-Rad, 
Hercules, CA, USA).
ELISA. The other half of the brain and lung tissues were minced in RIPA lysis buffer and used to measure 
the levels of interleukin (IL)-6, monocyte chemotactic protein-1 (MCP-1), and regulated on activation, normal 
T cell expressed and secreted (RANTES) by ELISA (R&D Systems, Minneapolis, MN, USA) according to the 
manufacturer’s instructions. The optical density (O.D.) was read at A450 on a Synergy HTX plate reader (BioTek, 
Winooski, VT, USA).
Viability assay. Viability of microglia was assessed using a live/dead cell fluorescence assay which combines 
fluorescent reagents to yield two-color discrimination of the population of live cells indicated by green fluores-
cence from the dead-cell population indicated by red fluorescence (ScienCell Research Laboratories). Cells were 
imaged using an inverted fluorescence microscope (Zeiss) and viable cells were manually quantified and reported 
as percent of viability.
Statistical analysis. Data were analyzed using analysis of variance (ANOVA) techniques followed by 
Bonferonni’s post hoc test for multiple comparisons (GraphPad Prism 6 software, La Jolla, CA, USA). A value of 
p < 0.05 was considered significant.
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